Subramanian Loganathan

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (27)

• Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial
  Expert Opinion on Biological Therapy 2025 DOI: 10.1080/14712598.2025.2576506
  +Save
• Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study
  Expert Opinion on Biological Therapy 2025 DOI: 10.1080/14712598.2025.2538608
  +Save
• Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability
  Advances in Therapy 2025 DOI: 10.1007/s12325-025-03240-5
  +Save
• Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: results from the Study to Test pharmacokinetic BioEquival…
  Expert Opinion on Investigational Drugs 2025 DOI: 10.1080/13543784.2025.2500334
  +Save
• An open-label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability
  Diabetes Obesity and Metabolism 2025 DOI: 10.1111/dom.16327
  +Save
• Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial
  JAMA Ophthalmology 2024 DOI: 10.1001/jamaophthalmol.2024.3458
  +Save
• Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus
  Drugs 2023 DOI: 10.1007/s40265-023-01925-1
  +Save
• Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study
  Diabetes Obesity and Metabolism 2023 DOI: 10.1111/dom.14994
  +Save
• Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer
  European Journal of Drug Metabolism and Pharmacokinetics 2023 DOI: 10.1007/s13318-023-00855-3
  +Save
• REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT
  Expert Opinion on Biological Therapy 2023 DOI: 10.1080/14712598.2023.2204186
  +Save